Anterior uveitis market is anticipated to witness lucrative growth over the forecast period owing to increasing prevalence of chronic diseases such as trauma to the eye, rheumatoid arthritis, rubella and mumps. It is an inflammation of middle layer in the eyes and generally includes ciliary body, iris and choroid. Increasing rate of optical infection coupled with rising awareness about treatment of anterior uveitis is likely to propel the market growth over the forecast period. Furthermore, increasing personal disposable income, high expenditure in healthcare sector and favorable government regulation are some other major drivers of this market. The group of pigmented or non-pigmented tissues are commonly known as uvea, which generally found in the middle among all three layers that forms the eye. Redness of eyes, blurring of vision, small size of pupil and sensitivity to light can be possible symptoms of anterior uveitis, which is needed to be treated otherwise it can result in permanent blindness. The developing nations provides significant growth opportunity due to the presence of large untapped market coupled with rising level of awareness about anterior uveitis.
The global anterior uveitis market is segmented on the basis of treatment and end use. By treatment, the market is further divided into corneal ulcers, anti TNF agents and cyclopegics/ ciliary muscles relaxants. Corneal ulcers is anticipated to witness lucrative growth over the forecast period owing to increasing incidences in corneal infection and disorders such as cataract or glaucoma. On the basis of end use, the global anterior uveitis market is segmented into hospitals, clinics and research institutes. Hospitals segment is anticipated to show lucrative growth over the forecast period owing to increasing awareness about treatments of anterior uveitis market coupled with rising government support and policies.
Geographically, the global anterior uveitis market is studied under five main regions namely North America, Latin America, Asia Pacific, Europe and MEA. The developed region such as North America and Europe is anticipated to witness increasing incidences of anterior uveitis compared to other developing nations like India, China, Brazil, Myanmar, Philippines, and other countries in Asia Pacific region. North America, Latin America, and Europe are more prone towards this disease followed by MEA and Asia Pacific due to their facilities and diagnosis of uveitis at earlier stage coupled with high level of awareness.
Some of the companies producing drugs for anterior uveitis are Amdipharm Mercury Company Limited, Novartis AG and Santen Pharmaceuticals to name a few. The global anterior uveitis market is oligopolistic and consolidated in nature. The new firm faces barrier in entering into the firm as the price of firm’s product is highly dependent other firm’s price. Firms goes through many mergers, strategic collaboration, new product development, acquisition and geographical expansion as a business development activity to gain the maximum share in the long run.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.